Kohima News Paper

B-Cell Non-Hodgkin Lymphoma Market to Observe Stupendous Growth During the Forecast Period 2032 | Key Companies – MorphoSys, Pharmacyclics, Xynomic, BeiGene, Celgene, Pfizer, Merck, AbbVie, and Others

 Breaking News
  • No posts were found

B-Cell Non-Hodgkin Lymphoma Market to Observe Stupendous Growth During the Forecast Period 2032 | Key Companies – MorphoSys, Pharmacyclics, Xynomic, BeiGene, Celgene, Pfizer, Merck, AbbVie, and Others

April 27
19:00 2022
B-Cell Non-Hodgkin Lymphoma Market to Observe Stupendous Growth During the Forecast Period 2032 | Key Companies - MorphoSys, Pharmacyclics, Xynomic, BeiGene, Celgene, Pfizer, Merck, AbbVie, and Others
Delveinsight Business Research LLP
DelveInsight’s “B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the B-Cell Non-Hodgkin Lymphoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The B-Cell Non-Hodgkin Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

B-Cell Non-Hodgkin Lymphoma Market

B-Cell Non-Hodgkin Lymphoma: An Overview

NHL is a type of blood cancer that initially started in the white blood cells (WBCs) called lymphocytes, it is also known as non-Hodgkin’s disease. Commonly the NHL occurs from lymph nodes at one or more places in the body, which can progress through the lymphatic system from one group of lymph nodes to another. It can occur at any age and is often marked by enlarged lymph nodes, fever, night sweats, and weight loss. There are different types of NHL, and these are divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can and can develop from either B-cells or T-cells. Most of the cases of NHL are B-cell NHL.

B-Cell Non-Hodgkin Lymphoma Market Key Facts

  • As per DelveInsight, the total incident cases of NHL in the 7MM was 166,900+ in 2017, and are expected to increase during the study period. Furthermore, in the 7MM, the total cases of B-cell NHL were 141,800+.

  • Among the 7MM, the highest Incident population of B cell-NHL was in the United States, i.e., 61,000+ B-cell NHL cases in 2017.

  • Among the European 5 countries, Germany had the highest incident population of B-cell NHL, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident cases of B-cell NHL in 2017.

B-Cell Non-Hodgkin Lymphoma Market

B-Cell Non-Hodgkin Lymphoma market size shall increase significantly during the forecast period owing to the launch of upcoming therapies and the active participation of prominent pharma companies in the therapeutics domain.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted B-Cell Non-Hodgkin Lymphoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the B-Cell Non-Hodgkin Lymphoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

B-Cell Non-Hodgkin Lymphoma Epidemiology

The epidemiology section provides insights into the historical and current B-Cell Non-Hodgkin Lymphoma Epidemiology trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.

B-Cell Non-Hodgkin Lymphoma Epidemiology Segmentation – 

  • Total Incidence of NHL

  • Total Incidence of B-cell NHL

  • Gender-specific Incidence of B-cell NHL

  • Age-specific Incidence of B-cell NHL

  • Subtype-Specific Incidence of B-cell NHL

  • Stage-Specific Incidence of B-cell NHL

B-Cell Non-Hodgkin Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the B-Cell Non-Hodgkin Lymphoma market or expected to get launched during the study period. The analysis covers B-Cell Non-Hodgkin Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the B-Cell Non-Hodgkin Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market

B-Cell Non-Hodgkin Lymphoma Therapeutics Analysis

The B-cell NHL market dynamics is anticipated to change in the coming years owing to the launch of emerging therapies.

Several major Pharma giants are thoroughly working toward the development of new treatment therapies in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with B-cell NHL.

Some of the key companies in the B-Cell Non-Hodgkin Lymphoma Market include:

  • BeiGene

  • Pfizer

  • Epizyme

  • Novartis

  • Verastem

  • Gilead Sciences

  • AstraZeneca

  • Merck Sharp & Dohme

  • Bristol-Myers Squibb

  • Gilead Sciences

  • MorphoSys AG

  • TG Therapeutics

  • Hoffmann-La Roche

  • Janssen

  • Spectrum Pharmaceuticals

  • Takeda

  • Millennium Pharmaceuticals

  • Pharmacyclics 

  • AbbVie Company

  • Celgene Corporation

  • Xynomic Pharmaceuticals

And many others.

B-Cell Non-Hodgkin Lymphoma Therapies covered in the report include:

  • Avelumab

  • KTE-X19

  • Tafasitamab

  • Abexinostat

  • Tazemetostat

  • Umbralisib

  • Lisocabtagene maraleucel

  • Brukinsa (Zanubrutinib)

  • Polivy (Polatuzumab vedotin)

  • Venetoclax (ABT199)

  • Kymriah (tisagenlecleucel)

  • Copiktra (Duvelisib)

  • Imbruvica (Ibrutinib)

  • Zydelig (Idelalisib)

  • Revlimid (lenalidomide)

  • Keytruda (Pembrolizumab)

  • Aliqopa (Copanlisib; BAY 80-6946)

  • Yescarta (Axicabtagene ciloleucel; KTE-C19)

  • Calquence (Acalabrutinib)

  • Gazyva (Obinutuzumab, GA-101)

  • Velcade (bortezomib)

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. B-Cell Non-Hodgkin Lymphoma Competitive Intelligence Analysis

4. B-Cell Non-Hodgkin Lymphoma Market Overview at a Glance

5. B-Cell Non-Hodgkin Lymphoma Disease Background and Overview

6. B-Cell Non-Hodgkin Lymphoma Patient Journey

7. B-Cell Non-Hodgkin Lymphoma Epidemiology and Patient Population

8. B-Cell Non-Hodgkin Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. B-Cell Non-Hodgkin Lymphoma Unmet Needs

10. Key Endpoints of B-Cell Non-Hodgkin Lymphoma Treatment

11. B-Cell Non-Hodgkin Lymphoma Marketed Products

12. B-Cell Non-Hodgkin Lymphoma Emerging Therapies

13. B-Cell Non-Hodgkin Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. B-Cell Non-Hodgkin Lymphoma Market Outlook (7 major markets)

16. B-Cell Non-Hodgkin Lymphoma Access and Reimbursement Overview

17. KOL Views on the B-Cell Non-Hodgkin Lymphoma Market.

18. B-Cell Non-Hodgkin Lymphoma Market Drivers

19. B-Cell Non-Hodgkin Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Narcolepsy Market

DelveInsight’s “Narcolepsy Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology, market size, share, trends as well as emerging therapies and the key companies in the Narcolepsy therapeutics landscape.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/